when the condition
is serious
IFR Center for Current Research
CRITICAL FINDINGS FROM TOP MEDICAL JOURNALS
|
SearchErectile Dysfunction: Free Medical and Health Information on Erectile Dysfunction Research and TreatmentErectile Dysfunction
Search within these results:
BACKGROUND: Erectile dysfunction is common among men aged more than 60 years.
Tampere, Finland Finland Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafi
OBJECTIVE: Recent high-profile medicine withdrawals have highlighted the complex decision-making process that regulators, pharmaceutical companies, prescribers, and patients must undertake in determining whether a drug has an appropriate benefit-risk balance.
New York, NY 10017 USA Premature ejaculation (PE) is ejaculation occurring without control, on or shortly after vaginal penetration and before the subject wishes it, causing marked distress or interpersonal difficulties.
Perth, Western Australia Australia Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with
INTRODUCTION: Elderly men are bothered by lower urinary tract complaints designated as lower urinary tract symptoms (LUTS).
Moscow, Russia Russia Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabeti
Diabetes mellitus (DM) is an established risk factor predisposing to male erectile dysfunction (ED), and it has been calculated that more than 50% of diabetic men develop ED within ten years of diagnosis.
Room 37, Viale Policlinico 155
Rome, Italy 00161 Italy The treatment of erectile dysfunction (ED) has been revolutionized during the last 2 decades with several treatment options now available.
Thessaloniki, Greece Greece Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction
The relationship between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) caused by benign prostatic obstruction (BPO) has recently gained increasing attention.
New Orleans, Louisiana USA Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimizati
OBJECTIVE To test the hypothesis that a variable dosage of the oral phosphodiesterase type 5 (PDE5) inhibitor sildenafil (25, 50, 100 mg) or vardenafil (5, 10, 25 mg) determined according to results obtained from nocturnal penile tumescence and rigidity (NPTR, RigiScan), given nightly for 1 year, can improve spontaneous erectile function (EF) in men with mild-to-moderate arteriogenic erectile dysfunction (ED); this regimen was compared with a fixed daily dosage of sildenafil 25 mg or vardenafil
Remsheid, Germany Germany Daily Vardenafil for 6 Months Has No Detrimental Effects on Semen Characteristics or Reproductive Ho
PURPOSE: Phosphodiesterase type 5 inhibitors are the first choice therapy in the treatment of erectile dysfunction.
Toronto, Ontario Canada |
PartnersLinksApproved By
|
